



BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS" 299 THAMBU CHETTY STREET, CHENNAI - 600 001, INDIA.
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com
CIN:L24294 TN1995PLCO30698

BPL SE CS LODR 37/2023.

To,

October 30, 2023

Listing Department, BSE Limited, P J Towers, Dalal Street, Mumbai – 400001.	Listing Department, National Stock Exchange of India, Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051.
Security Code: 532989 Security ID: BAFNAPHARM	Symbol: BAFNAPH Series: EQ.

Dear Sir/Madam,

Subject: Intimation of meeting of Board of Directors – Approval of Q2 FY24 Financial Results.

Reference: BPL SE CS PIT 33/2023 dated September 29, 2023.

We would like to bring to your notice that a meeting of Board of Directors of the Company is scheduled to be held on Thursday, November 09, 2023, inter-alia, to consider and approve the Un-Audited Standalone Financial Results of the Company for the second quarter of FY24 and half year ended September 30, 2023, together with the 'Limited Review Report' for the said period.

This intimation is given pursuant to Regulations 29(1) and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In terms of SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window to deal in the equity shares of the Company, by the designated employees, is closed since October 01, 2023, and shall remain closed up to November 11, 2023 (both days inclusive). The said information for the financial year 2023-24 is already made available on the website of the Company.

This intimation shall also be available on the Company's website www.bafnapharma.com

Kindly take the information on record.

Thank you,

Yours faithfully,
For Bafna Pharmaceuticals Limited,

(Vishnu V. Kuppa)
Company Secretary & Compliance Officer.